trimetrexate has been researched along with Leukemia, T-Cell in 3 studies
Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.
Leukemia, T-Cell: A malignant disease of the T-LYMPHOCYTES in the bone marrow, thymus, and/or blood.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Asai, S | 1 |
| Miyachi, H | 3 |
| Kobayashi, H | 3 |
| Takemura, Y | 3 |
| Ando, Y | 3 |
3 other studies available for trimetrexate and Leukemia, T-Cell
| Article | Year |
|---|---|
Large diversity in transport-mediated methotrexate resistance in human leukemia cell line CCRF-CEM established in a high concentration of leucovorin.
Topics: Amino Acid Substitution; Antimetabolites, Antineoplastic; Biological Transport; Carrier Proteins; Co | 2003 |
Expression of variant dihydrofolate reductase with decreased binding affinity to antifolates in MOLT-3 human leukemia cell lines resistant to trimetrexate.
Topics: Base Sequence; DNA Primers; Drug Resistance; Folic Acid Antagonists; Humans; In Vitro Techniques; Ki | 1995 |
Cytotoxicity of trimetrexate against antifolate-resistant human T-cell leukemia cell lines developed in oxidized or reduced folate.
Topics: Antimetabolites, Antineoplastic; Biological Transport; Cell Survival; Drug Resistance, Neoplasm; Dru | 1997 |